AC Immune S.A.
ACIU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 84.5% | 276.1% | – | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -129.1% | -268.9% | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -178% | -350.2% | -1,728.7% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -186.4% | -366.4% | -1,798% | – |
| EPS Diluted | -0.51 | -0.64 | -0.85 | -0.97 |
| % Growth | 20.3% | 24.7% | 12.4% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |